Cambridge, Massachusetts-based Common Sensing, which specializes in connected containers for injectable medications, has raised $6.6 million in Series A funding. The round was led by Waterline Ventures, with New World Health, Royal Philips, and Haselmeier also participating.
The funding will be used to accelerate manufacturing and commercial operations for Common Sensing’s GoCap, a dose and...
Pharmaceutical company Boehringer Ingelheim is partnering with Inovalon, a data analytics company that provides cloud-based platforms to the healthcare industry to facilitate the shift from volume to value-based care, on behalf of Boehringer Ingelheim’s diabetes alliance with Eli Lilly. Leveraging Inovalon’s platform, the partnership will work to support outcomes-based contracting, taking...
Medtronic. Dexcom. Abbott. Sanofi. Google. A lot of very large, well-known companies are investing heavily into innovating the diabetes space, and that innovation is exciting. But a disproportionate amount of the innovation around insulin delivery focuses on the insulin pump, a delivery device that’s only used by a small percentage of insulin users. Most insulin users — between 70 and 93 percent...
Common Sensing, a Cambridge-based company developing a smart connected insulin pen cap, announced that it will test its device in a clinical trial in collaboration with Joslin Diabetes Center, Sanofi, and Dexcom.
The study of 125 subjects will be conducted by Joslin and funded by Sanofi. Patients will be given a Gocap from Common Sensing, a cap that fits on to a disposable insulin pen and can...
